公开(公告)号：US10172907B2

公开(公告)日：2019-01-08

申请号：US13877955

申请日：2011-10-05

申请人： Anastasios Lymperopoulos ,  Walter J. Koch

发明人： Anastasios Lymperopoulos ,  Walter J. Koch

IPC分类号： A61P9/04 ,  A61K38/17 ,  A61K31/41 ,  A61K38/08 ,  A61K31/4184 ,  C07K14/47

摘要： The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of β-arrestin 1(βarr1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, β-arrestin 1(βarr1) is a therapeutic target for heart disease. The invention provides a βarr1 protein fragment comprising the C-terminus of βarr1 (βarr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of β-arrestin 1(βarr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of βarr1 activity and aldosterone production.

公开(公告)号：US20130274191A1

公开(公告)日：2013-10-17

申请号：US13877955

申请日：2011-10-05

申请人： Anastasios Lymperopoulos ,  Walter J. Koch

发明人： Anastasios Lymperopoulos ,  Walter J. Koch

IPC分类号： A61K38/08 ,  A61K31/41 ,  A61K31/4184

CPC分类号： A61K38/085 ,  A61K31/41 ,  A61K31/4184 ,  A61K38/1709 ,  A61P9/04 ,  C07K14/4703 ,  A61K2300/00

摘要： The disclosure describes the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of beta-arrestin I (beta.arr-1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, beta-arrestin I (beta.arr-1) is a therapeutic target for heart disease. Specifically, the disclosure provides a beta.arr-1 protein fragment comprising the C-terminus of beta.arr-1 (beta.arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of beta-arrestin (beta.arr-1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of beta.arr-1 activity and aldosterone production.

摘要翻译： 该公开内容描述了循环性强酮水平升高对心脏病和其它高醛状血糖状况的贡献。 由于血管紧张素II（AngII）1型受体（AT1R）的β-arrestin I（beta.arr-1）的激活介导AngII诱导的醛固酮生成，因此β抑制蛋白I（beta.arr-1）是治疗靶点 心脏病。 具体地，本公开提供了包含beta.arr-1（beta.arr1ct; SEQ ID NO：3）的C末端的beta.arr-1蛋白质片段，含有该蛋白质片段的组合物，以及使用该蛋白质片段 通过抑制β-抑制蛋白（beta.arr-1）降低心脏病和其他醛固酮增多症状中醛固酮的水平升高。 这些组合物和方法在心肌梗塞（MI）后在慢性心力衰竭和进展为心力衰竭中具有治疗益处。 此外，本发明提供AngII肽类似物（SEQ ID NO：4），含有该类似物的组合物，以及使用该类似物刺激beta.arr-1活性和醛固酮产生的方法。

公开(公告)号：US20100048479A1

公开(公告)日：2010-02-25

申请号：US12513713

申请日：2007-11-09

申请人： Anastasios Lymperopoulos ,  Walter J. Koch

发明人： Anastasios Lymperopoulos ,  Walter J. Koch

IPC分类号： A61K38/16 ,  A61K31/711 ,  A61K31/7105 ,  A61P9/10

CPC分类号： A61K48/0075 ,  A61K48/0058 ,  C12N9/1205

摘要： The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function.

摘要翻译： 本发明涉及治疗失败的心脏的组合物和方法。 更具体地，本发明提供对肾上腺中G蛋白偶联受体激酶2活性的抑制，其例如降低儿茶酚胺分泌和失败心脏的交感负担，从而改善心脏肾上腺素能/肌力储备和 整体收缩功能。